PRSS1 and familial pancreatic carcinoma: In addition, we found that BRAF, PRSS1, PANBP2, RUNX1T1, and other genetic mutations were associated with efficacy of patients who receive combination treatment, but because of the small sample size, it was not possible to determine the significance of the mutant state in pancreatic cancer treatment (Table 4).